Colin R. Laughlin

669 total citations
2 papers, 7 citations indexed

About

Colin R. Laughlin is a scholar working on Molecular Biology, Hematology and Biotechnology. According to data from OpenAlex, Colin R. Laughlin has authored 2 papers receiving a total of 7 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Molecular Biology, 1 paper in Hematology and 1 paper in Biotechnology. Recurrent topics in Colin R. Laughlin's work include Gut microbiota and health (1 paper), Immune Response and Inflammation (1 paper) and Iron Metabolism and Disorders (1 paper). Colin R. Laughlin is often cited by papers focused on Gut microbiota and health (1 paper), Immune Response and Inflammation (1 paper) and Iron Metabolism and Disorders (1 paper). Colin R. Laughlin collaborates with scholars based in United States. Colin R. Laughlin's co-authors include Marlies Meisel, Catherine M. Phelps, Sébastien Gingras and Rachel A. Gottschalk and has published in prestigious journals such as The Journal of Immunology and STAR Protocols.

In The Last Decade

Colin R. Laughlin

2 papers receiving 7 citations

Peers

Colin R. Laughlin
A Youssef Australia
Alex Hakansson United States
Ann Rowley United States
Y. Yu China
Jonathan Bermeo Australia
Catherine M. Phelps United States
Erik Storrs United States
A Youssef Australia
Colin R. Laughlin
Citations per year, relative to Colin R. Laughlin Colin R. Laughlin (= 1×) peers A Youssef

Countries citing papers authored by Colin R. Laughlin

Since Specialization
Citations

This map shows the geographic impact of Colin R. Laughlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin R. Laughlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin R. Laughlin more than expected).

Fields of papers citing papers by Colin R. Laughlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin R. Laughlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin R. Laughlin. The network helps show where Colin R. Laughlin may publish in the future.

Co-authorship network of co-authors of Colin R. Laughlin

This figure shows the co-authorship network connecting the top 25 collaborators of Colin R. Laughlin. A scholar is included among the top collaborators of Colin R. Laughlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin R. Laughlin. Colin R. Laughlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

2 of 2 papers shown
1.
Laughlin, Colin R., et al.. (2024). Fth1-mScarlet Reports Monocyte State during Lipopolysaccharide-induced Lung Inflammation. The Journal of Immunology. 213(10). 1508–1515. 1 indexed citations
2.
Phelps, Catherine M., et al.. (2023). Detection of viable commensal bacteria in murine melanoma tumors by culturomics. STAR Protocols. 4(3). 102492–102492. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026